The Global Tocilizumab Market Size Was Valued at USD 81.19 Million in 2023 and is Projected to Reach USD 228.96 Billion by 2032, Growing at a CAGR of 12.20%.
Tocilizumab (marketed primarily as Actemra) is a breakthrough therapeutic agent a humanized monoclonal antibody specifically designed to target the interleukin-6 (IL-6) receptor. By binding to this receptor, Tocilizumab effectively blocks...
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek